Pfizer's mini-dystrophin gene therapy fordadistrogene movaparvovec failure in the Duchenne muscular dystrophy treatment opens new opportunities for several pharmaceutical companies such as Sarepta Therapeutics (SRP-5051), Santhera Pharmaceuticals/ReveraGen BioPharma (Vamorolone), Taiho Pharmaceutical (TAS-205), FibroGen (Pamrevlumab), and others, to advance their therapies and potentially dominate the DMD market.
Santhera Pharmaceuticals has announced that its partner Sperogenix Therapeutics has launched a paid-for Early Access Program (EAP) for Agamree (vamorolone) in China for patients with Duchenne muscular dystrophy (DMD).
Pratteln, Switzerland, June 10, 2024 – Santhera Pharmaceuticals (SIX: SANN) announces that its partner Sperogenix Therapeutics has launched a paid-for Early Access Program (EAP) for AGAMREE®...
Pratteln, Switzerland, March 27, 2024 “ Santhera Pharmaceuticals (SIX: SANN) announces that the China National Medical Products Administration (NMPA) has accepted for priority review the new drug...
Santhera™s Partner Catalyst Launches AGAMREE® (Vamorolone) in the United States
CORAL GABLES, Fla., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst or Company) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused...
Results from 112 patients with DMD who completed the study confirm maintenance of efficacy and benefits in safety and tolerability of treatment with vamorolone over 48 weeks AGAMREE® has shown safety...
Santhera Launches AGAMREE in Germany as First Market for DMD
Santhera Receives Approval for AGAMREE as a Treatment for DMD
Santhera’s Agamree gains EU approval for Duchenne muscular dystrophy